東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Synthetic and biological studies on ...

Pepe, Antonella.

Linked to FindBook

Google Book

Amazon

博客來

Synthetic and biological studies on new anti-tumor agents.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Synthetic and biological studies on new anti-tumor agents./
Author:	Pepe, Antonella.
Description:	155 p.
Notes:	Source: Dissertation Abstracts International, Volume: 66-09, Section: B, page: 4825.
Contained By:	Dissertation Abstracts International66-09B.
Subject:	Chemistry, Pharmaceutical. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3189423
ISBN:	0542321459

Synthetic and biological studies on new anti-tumor agents.
Pepe, Antonella.

Synthetic and biological studies on new anti-tumor agents. - 155 p.

Source: Dissertation Abstracts International, Volume: 66-09, Section: B, page: 4825.

Thesis (Ph.D.)--State University of New York at Stony Brook, 2005.

Forty years after its discovery, Paclitaxel still offers attractive challenges for chemists and biologists. Taxol chemotherapy is associated with undesirable side effects due to the lack of specificity towards tumor cells and the development of cancers expressing MDR phenotype. More research is required to further extend the acquired knowledge and reduce those limits.

ISBN: 0542321459Subjects--Topical Terms:

550957
Chemistry, Pharmaceutical.

Synthetic and biological studies on new anti-tumor agents.
LDR:03589nmm 2200337 4500 001 1815745
005 20060710080822.5
008 130610s2005 eng d
020 $a 0542321459
035 $a (UnM)AAI3189423
035 $a AAI3189423
040 $a UnM $c UnM
100 1 $a Pepe, Antonella. $3 1905155
245 1 0 $a Synthetic and biological studies on new anti-tumor agents.
300 $a 155 p.
500 $a Source: Dissertation Abstracts International, Volume: 66-09, Section: B, page: 4825.
500 $a Adviser: Iwao Ojima.
502 $a Thesis (Ph.D.)--State University of New York at Stony Brook, 2005.
520 $a Forty years after its discovery, Paclitaxel still offers attractive challenges for chemists and biologists. Taxol chemotherapy is associated with undesirable side effects due to the lack of specificity towards tumor cells and the development of cancers expressing MDR phenotype. More research is required to further extend the acquired knowledge and reduce those limits.
520 $a Our research is essentially focused on the further expansion of paclitaxel's existing SAR studies, and on the development of tumor targeting strategies.
520 $a A new approach has been evaluated to increase the tumor uptake of second generation taxoids, especially active against multi drug resistant cancers. Polyunsaturated fatty acids such as docosahexanoic acid, linolenic acid and linoleic acid were linked at the C2'-position of the second generation taxoids already developed in these laboratories. The new conjugates exhibited strong activity against a drug-sensitive human ovarian tumor xenograft and a human colon tumor xenograft, overexpressing Pgp glycoprotein and resistant to anticancer agents including paclitaxel and docetaxel.
520 $a The increasing interest recently devoted to the synthesis of biologically active compounds containing fluorine atoms, led us to extend our structure-activity relationship studies to C-3'-difluoro- and C-3'trifluoromethyl advanced second generation taxoids. Optimization of the synthesis and enzymatic resolution of fluorinated beta-lactam, has provided easily accessible fluorinated taxoids side chains. We synthesized paclitaxel analogs with multiple modifications, at C-2, C-3' and C-10.
520 $a SAR studies on paclitaxel over the last 15 years confirmed the importance of the baccatin core to the anticancer activity of this important drug. One of the few exceptions discovered so far is IDN5390 a novel taxoid with the C-ring of the taxane skeleton cleaved. This novel C-seco taxoid is a promising drug candidate to deal with non-MDR based resistance to paclitaxel caused by the upregulation of the class III beta-tubulin. It has been recently shown that some mammalian cells resistant to paclitaxel overexpress specific beta-tubulin classes. In particular, in ovarian tumors from cancer patients the upregulation of the class III beta-tubulin confers this type of resistance to paclitaxel. Microtubules composed of the class III beta-tubulin are by far more sensitive to IDN5390 than to paclitaxel. These results led us to design a series of IDN5390 analogs. The synthesis and SAR studies of these novel C-seco taxoids will be discussed, with a focus on their ability to interact with overexpressed class III beta-tubulin.
590 $a School code: 0771.
650 4 $a Chemistry, Pharmaceutical. $3 550957
650 4 $a Health Sciences, Pharmacy. $3 1017737
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0491
690 $a 0572
690 $a 0419
710 2 0 $a State University of New York at Stony Brook. $3 1019194
773 0 $t Dissertation Abstracts International $g 66-09B.
790 1 0 $a Ojima, Iwao, $e advisor
790 $a 0771
791 $a Ph.D.
792 $a 2005
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3189423